Further Research on Resveratrol Shows Promise for Treatment of Pancreatic Cancer
While disabling the function of the cancer cells by reaching and reacting with the mitochondria (the cell's energy source), researchers found that when they were pre-treated with resveratrol before being irradiated, it resulted in a type of cell death called apoptosis. This is an important goal of cancer therapy.
According to Paul Okunieff, chief of radiation oncology at the University of Rochester Medical Centre, "Antioxidant research is very active and very seductive right now (and) the challenge lies in finding the right concentration and how it works inside the cell. Resveratrol seems to have a therapeutic gain by making tumor cells more sensitive to radiation and making normal tissue less sensitive."
Okunieff began studying resveratrol as a tumor sensitizer, which is when the link to the mitochondria was uncovered. Researchers divided pancreatic cancer cells into two groups: cells treated without resveratrol then iodized, and ones treated with resveratrol at a relatively high dose of 50mg per ml before being iodized. The amount of resveratrol in red wine can vary between types of grapes and growing seasons, and ranges can be as high as 30 mg per ml. But the researchers said higher doses are expected to be safe as long as a physician monitors the patient. The study found that resveratrol reduced the function of proteins in the pancreatic cancer cell membranes responsible for pumping chemotherapy out of the cell, therefore making them more sensitive to the treatment. Additionally, the antioxidant triggered the production of reactive oxygen species (ROS), causing apoptosis, and depolarized the mitochondrial membranes, indicating a decrease in the cell's potential to function. The researchers said the discovery is important because the mitochondria contains its own DNA and can continuously supply the cell with energy when functioning fully. Stopping the energy flow can therefore help stop cancer.
Okunieff further stated that, "While additional studies are needed, this research indicated that resveratrol has a promising future as part of the treatment for cancer."
The Company's wholly-owned subsidiary, Nutritional Specialties, Inc./dba LifeTime(R), launched Resveratrol Life Tonic(TM) in liquid form for enhanced bioavailability. The product's powerful antioxidant properties include 300 mg of resveratrol extract in each one ounce serving, which is equivalent to 1,300 glasses of red wine.(a)
Baywood International, Inc. (OTC BB: BYWD) ("Baywood") is a nutritional science company that develops, markets and sells nutraceutical and nutritionally enhanced products and new age beverages under its own brands. Baywood merges its expertise in nutritional formulation with its leverage in sales and distribution to deliver the most effective and progressive products to market. Currently, Baywood's products are sold under three brands that are distributed into retail markets nationwide and internationally as follows:
-- LifeTime(R) - Available in independent and chain health food stores, natural grocery stores, and other direct-to-consumer channels both internationally and domestically (www.lifetimevitamins.com)
-- Baywood PURECHOICE(R), Baywood SOLUTIONS(R) and Complete La Femme(R) - Available in independent and chain health food stores, natural grocery stores, and other direct-to-consumer channels both internationally and domestically (www.baywoodproducts.com)
-- Mamajuana Energy(TM) - Available in select convenience stores and chain stores nationwide (www.mamajuanaenergy.com)
For more information, call (888) 350-0799, or for more information, visit Baywood's corporate website at www.bywd.com.
(a) These statements have not been evaluated by the Food & Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. The contents of this press release are not meant to be incorporated into the Company's website.
SOURCES: Advances in Experimental Medicine and Biology 2008;614:179-86 "Anti-cancer effect of resveratrol is associated with induction of apoptosis via a mitochondrial pathway alignment" Authors: Paul Okunieff, Weimin Sun, Wei Wang, Jung Kim, Shanmin Yang
This press release may contain forward-looking statements, made in reliance upon Section 21D of the Exchange Act of 1934, which involve known and unknown risks, uncertainties or other factors that could cause actual results to differ materially from the results, performance, or expectations implied by these forward-looking statements. The Company's expectations, among other things, are dependent upon general economic conditions, continued demand for its products, the availability of raw materials, retention of its key management and operating personnel, its ability to operate its subsidiary companies effectively, need for and availability of additional capital as well as other uncontrollable or unknown factors which are more fully disclosed in the Company's Form 10-KSBs and 10-QSBs on file with the United States Securities and Exchange Commission.
Baywood International, Inc.
Neil Reithinger, President & C.E.O.
480-951-3956, ext. 120
Posted: April 2008